Related Experiment Video
Updated: Aug 29, 2026

Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes
Published on: March 19, 2019
On risk and plant-based biopharmaceuticals
Robert K D Peterson1, Charles J Arntzen
1Agricultural and Biological Risk Assessment, Department of Entomology, Montana State University, Bozeman, MT 59717-3020, USA. bpeterson@montana.edu
Abstract:
Research into plant-based expression of pharmaceutical proteins is proceeding at a blistering pace. Indeed, plants expressing pharmaceutical proteins are currently being grown in field environments throughout the USA. But how are these plants and proteins being assessed for environmental risk and how are they being regulated? Here, we examine the applicability of the risk assessment paradigm for assessing human and ecological risks from field-grown transgenic plants that express pharmaceutical proteins.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Production of Pharmaceuticals
Biopharmaceutics and Pharmacokinetics: Overview
Preclinical Development: Overview
Bioequivalence studies: Biowaivers

